Reducing The Number Of Failures In Early Stage Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Reducing The Number Of Failures In Early Stage Development


Pharmaceutical Technology Europe
Volume 22, Issue 7

References

1. Association of Clinical Research Organizations, "Drug Development Process" (2009). http://www.acrohealth.org/

2. S. Marchetti and J.H.M. Schellens, Br. J. Cancer, 97, 577–581 (2007).

3. R.C. Garner and G. Lappin, Br. J. Clin. Pharmacol., 64(4), 367–370 (2006).

4. H. Eliopoulos et al., Clin. Cancer Res., 14(12), 3683–3688 (2008).

5. Boston Consulting Group, "Rising to the productivity challenge: a strategic framework for Biopharma" (2004). http://www.bcg.com/

6. Fund for the Replacement of Animals in Medical Experiments, FRAME UK, "Testing novel drugs in animals" (2010). http://www.frame.org.uk/

7. European Medicines Agency, "Position paper on non-clinical safety studies to support clinical trials with a single microdose" (2004). http://www.ema.europa.eu/

8. E. Abdoler et al., Clin. Cancer Res., 14(12), 3692–3697 (2008).

9. Outsourcing Pharma, "More Phase 0 studies needed to sway 'conservative pharma'" (2007). http://www.outsourcing-pharma.com/

10. FDA, "FDA's Critical Path Initiative" (2010). http://www.fda.gov/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here